20 décembre 2023
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.855.2407
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38117111
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E6F787905A168
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-06-20 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
N. Voide et al., « Épidémie de myopie en pédiatrie : prise en charge, prévention et traitement [Outbreak of myopia in pediatrics : management, prevention and treatment] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.855.2407
The worldwide incidence and prevalence of myopia has increased. The age of onset of this refractive disorder has inversely decreased. In addition to genetic and familial factors, environmental factors related to a sedentary lifestyle and activities in highly solicited near vision seem to have an impact on the development of axial myopia, that is an early and non-reversible elongation of the eyeball. Prevention of the development of myopia in pediatrics through simple daily measures plays therefore a fundamental role. In addition, pharmacological treatments, and specific optical treatments for controlling myopia have shown encouraging results in reducing the risk of long-term complications of progressive myopia, that is increased risk of developing cataract, glaucoma, retinal detachment, or maculopathy.